Levotuss (Levodropropizine)

Levodropropizine is used as a peripheral antitussive to control cough associated with respiratory tract irritation.

• Dry cough: provides symptomatic relief by reducing the cough reflex.
• Acute upper respiratory infection cough: alleviates coughing episodes during common colds.
• Chronic non‑productive cough: helps manage persistent cough when other causes have been excluded.

• Levodropropizine acts peripherally on the sensory nerve endings of the respiratory epithelium. By inhibiting the activation of vagal afferent fibers, it decreases the sensitivity of the cough reflex arc without penetrating the blood‑brain barrier. The drug does not bind to central opioid receptors, which limits central side effects and provides cough suppression through modulation of peripheral neurogenic inflammation and reduces the release of pro‑inflammatory mediators.

Levodropropizine may cause adverse reactions, which are generally mild but can be serious in rare cases.

Common Side Effects

• Nausea: mild stomach upset reported by some patients.
• Diarrhea: loose stools occurring occasionally.
• Headache: transient head discomfort.
• Dizziness: sensation of light‑headedness.

Serious or Rare Side Effects

• Allergic reactions: rash, urticaria, or angioedema requiring medical attention.
• Hepatic dysfunction: elevated liver enzymes or jaundice in rare cases.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

When prescribing levodropropizine, clinicians should consider the following precautions to ensure safe use.

• Pediatric use: dosage must be individualized and prescribed by a qualified healthcare professional.
• Renal impairment: use with caution; dose adjustment may be required in severe renal dysfunction.
• Hepatic impairment: monitor liver function and consider reduced dosing in patients with liver disease.
• Concomitant CNS depressants: observe for additive sedation, although central effects are minimal.
• Pregnancy and lactation: safety has not been established; avoid unless clearly needed.
• Store at ambient temperature: keep below 25 °C, in the original packaging, protected from moisture and light.

Levodropropizine can interact with other medicines; awareness of major and moderate interactions helps prevent adverse outcomes.

Major Interactions (Avoid)

• Combined use with other peripheral antitussives: may increase risk of excessive cough suppression.
• Co‑administration with strong CYP3A4 inhibitors (if metabolized via this pathway): may raise plasma levels and side‑effect risk.

Moderate Interactions (Monitor Closely)

• Opioid cough suppressants (e.g., codeine): monitor for additive sedation or respiratory depression.
• Antihistamines: may enhance antitussive effect, requiring observation.
• Antidepressants affecting serotonin: watch for rare serotonin‑related effects.